Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Cemiplimab reduces disease recurrence as adjuvant therapy for cutaneous...

Dr Danny Rischin - Peter MacCallum Cancer Centre, Melbourne, Australia

Cemiplimab reduces disease recurrence as adjuvant therapy for cutaneous squamous cell carcinoma ( Dr Danny Rischin - Peter MacCallum Cancer Centre, Melbourne, Australia )

Trastuzumab deruxtecan benefit for some advanced gastric cancers

Dr Kohei Shitara - National Cancer Center Hospital East, Kashiwa, Japan

Trastuzumab deruxtecan benefit for some advanced gastric cancers ( Dr Kohei Shitara - National Cancer Center Hospital East, Kashiwa, Japan )

HER2-positive breast cancer: Predicting pCR from clinicopathologic variables...

Dr Nadine M Tung - Beth Israel Deaconess Medical Center, Boston, USA

HER2-positive breast cancer: Predicting pCR from clinicopathologic variables and genomic testing ( Dr Nadine M Tung - Beth Israel Deaconess Medical Center, Boston, USA )

Perioperative durvalumab and FLOT chemo can reduce risk of recurrence for some...

Dr Yelena Janjigian - Memorial Sloan Kettering Cancer Center, New York, USA

Perioperative durvalumab and FLOT chemo can reduce risk of recurrence for some gastric cancers ( Dr Yelena Janjigian - Memorial Sloan Kettering Cancer Center, New York, USA )

Nivolumab/ipilimumab followed by BRAF/MEK inhibitors preferred sequence for...

Dr Michael B. Atkins - Georgetown Lombardi Comprehensive Cancer Center...

Nivolumab/ipilimumab followed by BRAF/MEK inhibitors preferred sequence for BRAF-positive advanced melanoma ( Dr Michael B. Atkins - Georgetown Lombardi Comprehensive Cancer Center, Washington, USA )

Making immune check point inhibitors for lung cancer cost-effective in LMICs

Dr Giulia Segafredo and Dr Dario Trapani

Making immune check point inhibitors for lung cancer cost-effective in LMICs ( Dr Giulia Segafredo and Dr Dario Trapani )

BCG combined with mitomycin offers improved adjuvant treatment regimen for high...

Prof Dickon Hayne - University of Western Australia, Perth, Australia

BCG combined with mitomycin offers improved adjuvant treatment regimen for high-risk NMIBC ( Prof Dickon Hayne - University of Western Australia, Perth, Australia )

ASCO 2025: Latest in EGFR positive NSCLC

Prof Pascale Tomasini, Prof Enriqueta Felip, Prof Nicolas Girard

ASCO 2025: Latest in EGFR positive NSCLC ( Prof Pascale Tomasini, Prof Enriqueta Felip, Prof Nicolas Girard )

CtDNA useful biomarker for muscle-invasive bladder cancer patients who received...

Prof Thomas Powles - Barts Cancer Institute, London, England

CtDNA useful biomarker for muscle-invasive bladder cancer patients who received perioperative durvalumab ( Prof Thomas Powles - Barts Cancer Institute, London, England )

Sasanlimab BCG combo improves outcomes in high-risk NMIBC

Prof Thomas Powles - Barts Cancer Institute, London, England

Sasanlimab BCG combo improves outcomes in high-risk NMIBC ( Prof Thomas Powles - Barts Cancer Institute, London, England )

ELCC 2025: Latest in EGFR positive NSCLC

Dr Antonio Passaro, Prof Nicolas Girard, Prof Raffaele Califano and Dr Anna...

ELCC 2025: Latest in EGFR positive NSCLC ( Dr Antonio Passaro, Prof Nicolas Girard, Prof Raffaele Califano and Dr Anna Minchom )

Treatment with BAY 2927088 led to durable responses in patients previously...

Prof Nicolas Girard - Institut Curie, Paris, France

Treatment with BAY 2927088 led to durable responses in patients previously treated HER2-mutant NSCLC ( Prof Nicolas Girard - Institut Curie, Paris, France )

More from ecancer